Table 1 Resistance to anti-tuberculosis drugs stratified by previous tuberculosis treatment and for patients infected with a Beijing or a non-Beijing strain.
From: The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia
New cases | Previously treated | Total | Beijing | Non-Beijing | OR (Beijing) (95% CI) | |
|---|---|---|---|---|---|---|
Total cases | 198 | 184 | 382 | 190 | 192 | |
Resistance to: | ||||||
Ethambutol | 14 (7%) | 47 (26%) | 61 (16%) | 49 (26%) | 12 (6%) | 5.2 (2.6–10.8) |
Rifampicin | 15 (8%) | 54 (30%) | 69 (18%) | 51 (27%) | 18 (9%) | 3.6 (1.9–6.6) |
Pyrazinamide | 6 (3%) | 24 (13%) | 30 (8%) | 22 (12%) | 8 (4%) | 3.0 (1.2–7.6) |
Streptomycin | 68 (3%) | 111 (60%) | 179 (47%) | 114 (60%) | 65 (34%) | 2.9 (1.9–4.6) |
Isoniazid | 47 (24%) | 108 (59%) | 155 (41%) | 99 (52%) | 56 (29%) | 2.6 (1.7–4.1) |
MDR-TB | 15 (8%) | 53 (29%) | 68 (18%) | 51 (27%) | 17 (9%) | 3.8 (2.0–7.1) |